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Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic disorders that are 
characterized by ineffective hematopoiesis, peripheral blood cytopenias, and a risk of leukemic 
transformation. Little is known about the relationships among genomic, transcriptomic, and hematopoietic 
abnormalities, especially those between splicing factor mutations and myelodysplastic hematopoiesis. 
Splicing factors represent a novel class of driver genes in MDS, with SF3B1, SRSF2, and U2AF1 being the 
most frequently mutated genes. Abnormal RNA splicing is thought to play a central role in the pathogenic 
mechanism of mutated splicing factors. Here we performed a comprehensive transcriptome analysis of MDS 
using transcriptome sequencing. The purpose of this study was to gain insight into the relationship between 
genomic and transcriptomic alterations, particularly including the effect of splicing factor mutations on RNA 
splicing. 
We enrolled 214 patients with myeloid neoplasms with myelodysplasia. Genomic DNA was 
available for 211 patients, for which targeted-capture sequencing was performed. RNA sequencing was 
performed on bone marrow mononuclear cells (BMMNCs, n=165) and CD34+ cells (n=100) obtained from 
214 patients, of whom 51 were analyzed for both cell fractions. Libraries for RNA sequencing were prepared 
from polyA-selected RNA. The sequencing reads were aligned to the human reference genome (hg19) using 
the RNA sequencing unified mapper version 2.0.4. Alternative splicing and differential expression analyses 
were performed using JuncBASE version 0.6 and edgeR, respectively. 
Targeted-capture sequencing revealed that 124 patients (58%) had mutations in one or more 
splicing factors, including SF3B1 (n=68 [32%]), SRSF2 (n=39 [18%]), and U2AF1 (n=14 [6.5%]). RNA 
sequencing revealed a total of 190,301 and 147,809 alternative splicing events in BMMNCs and CD34+ cells, 
respectively. Splice junction usage was compared between splicing factor-mutated and unmutated samples to 
detect alternative splicing events associated with each splicing factor mutation. The analyses were confined to 
two splicing factors, SRSF2 and SF3B1, for which sufficient numbers of mutated samples were available for 
both cell fractions. A total of 2,057 and 3,831 events were significantly associated with SRSF2 and SF3B1 
mutations, respectively, in either BMMNCs or CD34+ cells (q-value <0.01). 
Mutant SRSF2- and SF3B1-associated splicing events showed two different features. First, the 
patterns of alternative splicing differed substantially. The splicing pattern most frequently associated with 
SRSF2 mutation was altered exon usage, which was either inclusion or skipping of a ‘cassette’ exon. In sharp 
contrast, SF3B1 mutation was frequently associated with increased usage of alternative 3’ splice sites. Second 
difference was the specificity of alternative splicing events. Mutant SRSF2-associated alternative splicing 
events were not specific to the SRSF2-mutated samples, but were also observed in those without splicing 
factor mutations, resulting in modest changes in relative abundance of alternative isoforms. By contrast, the 
mutant SF3B1-associated altered 3’ splice sites were often observed almost exclusively in the mutated 
samples, and were barely detected in the controls. The enhanced expression of the abnormal 3’ splice sites in 
the SF3B1-mutated samples was validated by RT-PCR for several genes. 
We next assessed the significance of the splicing alterations at the transcript level. Alternative 
splicing events were classified into five groups: (1) truncating alterations, (2) non-truncating alterations, (3) 
alternative first coding exons, (4) alternative last coding exons, and (5) alterations in non-coding regions. 
Truncating alterations introduce a frameshift or a premature termination codon into a transcript. 
Non-truncating alterations yield an in-frame isoform with a nucleotide deletion or insertion. The alternative 3’ 
splice sites associated with SF3B1 mutation were often clustered around 10–30 bp upstream of canonical 3' 
splice sites, resulting in nucleotide insertion at authentic exon-exon junctions. Of 671 mutant 
SF3B1-associated alternative 3’ splice sites, 373 (56%) yielded an out-of-frame transcript or introduced a 
premature termination codon, while 192 (29%) were non-truncating events. SRSF2 mutation was frequently 
associated with alternative exon usage that resulted in truncated isoforms. This includes usage of cryptic 
exons harboring a premature termination codon, and inclusion or skipping of out-of-frame exons. 
Truncating splicing alterations are likely to have deleterious effects on gene function through 
reduction of their authentic transcripts. To assess their effects, comprehensive analysis of differential gene 
expression was performed between the SRSF2- and SF3B1-mutated CD34+ cells and those without splicing 
factor mutations. The expression level of transcripts without truncating splicing alterations was estimated 
from the fraction of reads that showed alternative splicing. Target genes of mutant SF3B1-associated 
alternative 3’ splice sites showed a highly consistent reduction in the authentic transcripts; 145 of 290 (50%) 
target genes expressed in the CD34+ fraction were significantly down-regulated (q-value<0.01). Furthermore, 
down-regulation associated with aberrant 3’ splice sites represented by far the most significant changes in 
gene expression. Such highly significant changes were not detected for other splicing patterns of the mutant 
SF3B1-associated alterations, or for all the mutant SRSF2-associated events. 
We next focused on individual target genes of splicing alterations with a moderate to large effect 
size. These criteria were met in 358 of 3,831 (9.3%) mutant SF3B1-associated alterations, which involved 316 
genes as functional candidates. SF3B1 mutation is strongly associated with myelodysplastic syndrome with 
ring sideroblasts characterized by defects in heme biosynthesis and iron accumulation to mitochondria. The 
candidates of functional targets included genes related to heme biosynthesis and iron metabolism: ABCB7, 
PPOX, and TMEM14C. ABCB7 is a causative gene for an inherited sideroblastic anemia, whose 
haploinsufficiency has been shown to cause iron accumulation to mitochondria. ABCB7 was one of the most 
significantly down-regulated genes with an aberrant 3’ splice site in the SF3B1-mutated samples. The 
alternative 3’ splice site was located at 21 bp upstream from the authentic junction, of which usage led to 
insertion of a nucleotide sequence harboring a premature termination codon. PPOX, a gene encoding the 
penultimate enzyme of heme biosynthesis that catalyzes the oxidation of protoporphyrinogen IX to form 
protoporphyrin IX, also had an alternative 3’ splice site associated with SF3B1 mutation at 32 bp upstream of 
the canonical one, introducing a frameshift. It was also recapitulated by expression of the SF3B1K700E mutant. 
TMEM14C is an inner mitochondrial membrane protein that facilitates the import of protoporphyrinogen IX 
into the mitochondrial matrix and synthesis of protoporphyrin IX by PPOX. Mutant SF3B1-associated 
transcripts had an alternative 3’ splice site located in the 5’-untranslated region, the usage of which neither 
altered the amino acid sequence, nor had an effect on gene expression as evaluated by luciferase assay. 
Collectively, SF3B1 mutation induces usage of aberrant 3’ splice sites in two genes related to heme 
biosynthesis, ABCB7 and PPOX, leading to down-regulation of their authentic transcripts. It should be 
experimentally assessed whether reduced expression of ABCB7 and PPOX cooperatively contribute to 
development of anemia. 
The candidates of functional targets of mutant SF3B1-associated splicing alterations included 
cancer-related genes: tumor suppressors including NF1, DICER1, PML, PDS5A, and PPP2R5A, as well as an 
oncogene PTPN11. All of their splicing alterations were usage of alternative 3’ splice sites. NF1, DICER1, 
PML, PDS5A, PPP2R5A, and PTPN11 had truncating splicing alterations, associated with reduction in their 
authentic transcripts. 
SRSF2 mutation was mainly associated with modest changes in alternative splicing. However, 
despite a modest effect of an individual event, we found that EZH2 had multiple truncating splicing 
alterations associated with SRSF2 mutation. EZH2, a gene encoding the catalytic component of the polycomb 
repressive complex 2, acts as a tumor suppressor with recurrent loss-of-function mutations in myeloid 
malignancies. SRSF2-mutated samples showed an increased inclusion of a cryptic exon of EZH2 harboring a 
premature termination codon. We also identified an association between SRSF2 mutation and skipping of 
exon 11 as another alteration, which also led to a premature termination. Occurring independently from each 
other, these 2 cassette exons cooperatively contributed to down-regulation of the authentic transcript of EZH2. 
We also identified an additional targets of mutant SRSF2-associated splicing alterations potentially involved 
in the development of myelodysplasia: CASP8, and CDK10. Mutant SRSF2-associated exon skipping 
generated a prematurely terminating transcript, leading to a significant reduction of the authentic transcripts. 
High frequency of splicing factor mutations is a cardinal feature of MDS. Although 
myelodysplasia is a common clinicopathological presentation of splicing factor-mutated neoplasms, different 
mutations are associated with specific disease subtypes, such as those showing increased ring sideroblasts 
with SF3B1 mutations and myeloproliferative subtypes with mutated SRSF2. Through a comprehensive 
transcriptome analysis of a large cohort, we demonstrated that different splicing factor mutations had distinct 
effects on RNA splicing. We also revealed precise targets of splicing alterations across a wide variety of 
genes that did not largely overlap among different splicing factor mutations. These results provide insights 
into the molecular basis of the distinct phenotypes for different splicing factor mutations, highlighting 
potential oncogenic activity of mutant splicing factors through multiple splicing alterations in cancer-related 
genes. 
We also performed clustering analysis of gene expression profiles. Gene expression-based 
classification of MDS has not been established. Clustering analysis was first performed on gene expression 
profiles of bone marrow CD34+ cells from 100 cases. Gene expression data were filtered to 3,142 genes with 
large dispersion than those with similar mean expression level (trended dispersion). Consensus clustering 
using expression levels of 3,142 genes identified two robust subgroups, with clustering stability decreasing 
for the number of clusters ≥3. In other words, K-means clustering on the basis of global gene expression 
profiles was most stable when the samples were broadly classified into two subgroups. The first subgroup was 
characterized by a lower blast count and the up-regulation of genes specifically expressed in erythroid 
lineages, while the second one was significantly associated with increased expression of the genes related to 
stem/progenitor cells. Clinical outcomes also differed substantially; compared to the first subgroup, the 
second subgroup was significantly associated with survival in either univariate (hazard ratio 5.0 [95% 
confidence interval (CI), 1.8–14], P<0.001) or multivariate analysis (hazard ratio 6.8 [95% CI, 1.5–32], 
P=0.015). Notably, no leukemic transformation occurred in the first subgroup, which contrasted with the high 
leukemic transformation rate in the second subgroup (38%). The prognostic significance of this gene 
expression-based classification was validated in an independent cohort. Finally, we constructed a logistic 
regression model to predict these subgroups based on gene expression of unfractionated BMMNCs. Predicted 
high-risk subgroup was again significantly associated with poor prognosis in either univariate or multivariate 
analysis. This newly developed molecular classification will improve risk prediction and treatment 
stratification of MDS. 
 
